Miracor Medical SA
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Miracor Medical SA
When it comes to treating acute heart attack patients, primary percutaneous coronary intervention (PPCI) remains the gold standard of care. And while this life-saving procedure restores blood flow through the coronary artery, perfusion in all areas of the heart may not occur. In this article, we'll highlight three innovative medtech companies that have developed very different solutions to try to improve upon the current standard of care and hear perspectives from interventional cardiologists.
Hindsight 20/20 is a Q&A feature where medtech industry veterans share their long experience taking diverse businesses – be they start-ups or publicly-listed entities – from strength to strength and navigating through times of crises. In this installment, Jon H. Hoem, whose career in the cardiology sector spans more than two decades, explains how his thinking on building a robust clinical strategy has changed; why he believes you should never skimp on hiring talent; and advises on the difficult patches start-ups might hit and how to navigate around them, among other topics.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
- Medical Devices
- Other Names / Subsidiaries
- Miracor Medical Systems GmbH
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.